Shanghai-based biotechnology firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has declared the successful conclusion of the initial phase of a licensing agreement with Merck KGaA, concerning its proprietary colony stimulating factor-1 receptor (CSF-1R) inhibitor, pimicotinib (ABSK021). As part of this agreement, Abbisko has received an upfront payment of USD 70 million from the German pharmaceutical giant.
Pimicotinib, a highly selective and potent oral small-molecule antagonist of CSF-1R, was licensed to Merck for commercialization in Greater China, with an option for global development. This deal, inked in December of the previous year, could potentially be worth USD 605.5 million. The drug has garnered significant attention due to its breakthrough therapy designation (BTD) and priority review status in China, Europe, and the United States for the treatment of inoperable tenosynovial giant cell tumor (TGCT), a condition currently under Phase III investigation in both China and the US.
Moreover, a Phase II study of pimicotinib has been initiated for chronic graft-versus-host disease (cGVHD), while its potential in addressing multiple solid tumors and non-solid tumor indications, such as amyotrophic lateral sclerosis (ALS), is also under exploration.- Flcube.com
